BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study

Author:

Heise Tim1ORCID,Meiffren Grégory2,Alluis Bertrand2,Seroussi Cyril2,Ranson Aymeric2,Arrubla Jorge1,Correia José2,Gaudier Martin2,Soula Olivier2,Soula Rémi2,DeVries J. Hans1ORCID,Klein Oliver1,Bode Bruce3

Affiliation:

1. Profil Neuss Germany

2. Adocia Lyon France

3. Atlanta Diabetes Associates Atlanta Georgia

Funder

Adocia sponsored this study.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference16 articles.

1. Insulin Analogues

2. Ultra‐rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared with humalog in subjects with Type 1 diabetes mellitus;Andersen G;Diabetes,2016

3. Ultra‐rapid BioChaperone insulin Lispro (BC LIS): linear dose‐response and faster absorption than insulin Lispro (LIS);Andersen G;Diabetes,2015

4. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

5. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3